Circio
Develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.
Launch date
Employees
Market cap
$2.7m
Enterprise valuation
($13m) (Public information from Sep 2024)
Share price
NOK0.808 TRVX.OL
Company register number 996162095
Oslo Norway (HQ)
Financials
Estimates*
| NOK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.0m | - | 10.0m | <1m | - | 124m | 110m |
| % growth | (50 %) | - | - | (99 %) | - | - | (11 %) |
| EBITDA | (100m) | (94.0m) | (101m) | (98.7m) | (61.4m) | 18.7m | 98.0m |
| % EBITDA margin | (10000 %) | - | (1010 %) | (80268 %) | - | 15 % | 89 % |
| Profit | (108m) | (98.0m) | (103m) | (111m) | (63.5m) | 16.5m | 198m |
| % profit margin | (10800 %) | - | (1030 %) | (90000 %) | - | 13 % | 179 % |
| EV / revenue | 776.4x | - | 20.1x | 776.3x | - | -0.8x | 0.3x |
| EV / EBITDA | -7.8x | -3.1x | -2.0x | -1.0x | 1.6x | -5.4x | 0.3x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
NOK13.0m | Series A | ||
| N/A | $3.6m | Early VC | |
| N/A | $23.5m | Private Placement VC | |
| N/A | N/A | IPO | |
NOK8.2m | Grant | ||
* | N/A | NOK37.5m | Post IPO Debt |
| Total Funding | $29.7m | ||
Related Content
Recent News about Circio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Circio
Edit
ACQUISITION by Circio Jun 2015